Search
Close this search box.

Synaffic announces expansion of ADC collaboration with MacroGenics

  • MacroGenics adds up to four ADC programs
  • MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies
  • Synnafix expands collaboration which includes up to $2.2 billion in total potential payments plus tiered royalties on net sales 
 

AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has announced the expansion of its license agreement with MacroGenics Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. 

Synaffix’s expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net sales of any resulting products. MacroGenics currently has the option to pursue up to seven ADC programs under the expanded deal, which includes three programs from the original collaboration. 

Under the original licensing agreement, MacroGenics gained access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads (SYNtecan E™, SYNeamicin D™ and SYNeamicin G™), each designed to enable ADCs with best-in-class efficacy and tolerability. These may be combined with MacroGenics’ proprietary antibody and bispecific DART® platform technologies to generate next-generation ADCs.

Anthony DeBoer, Vice President of Business Development at Synaffix, said: “The expansion of our agreement with MacroGenics is a significant milestone for Synaffix that further underscores the growing momentum behind our proprietary ADC technology. There are now 13 companies that have publicly disclosed the development of more than 20 ADCs that were built using our technology, with 5 programs that have commenced clinical development to date. We look forward to continuing our close collaboration with the talented team at MacroGenics in order to deliver novel therapeutic candidates for patients in need.”

Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics, said: “MacroGenics continues to be excited about the promise of Synaffix’s novel drug-linker technology that can help advance multiple potential first and best-in-class ADCs for the treatment of cancer.” 

 Synaffix collaboration

Read more news here

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.